Evidence for specific analgesic activity of a muscarinic agonist selected among a new series of acetylenic derivatives

被引:13
作者
Barocelli, E
Ballabeni, V
Bertoni, S
De Amici, M
Impicciatore, M
机构
[1] Univ Parma, Ist Farmacol & Farmacognosia, I-43100 Parma, Italy
[2] Univ Milan, Ist Chim Farmaceut & Tossicol, I-20131 Milan, Italy
关键词
muscarinic agonists; oxotremorine; antinociception; central/peripheral cholinergic effects; in vivo pharmacology;
D O I
10.1016/S0024-3205(01)00973-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The central and peripheral effects of a series of Oxotremorine/Oxotremorine-M derivatives, previously characterized as muscarinic agonists in isolated preparations, were investigated in in vivo experiments. The molecules were tested for their antinociceptive activity (formalin licking and acetic acid writhing tests) and for their ability to induce tremor in mice. Peripheral cholinergic effects such as salivation, bradycardia, hypotension and intestinal hypermotility were studied in anaesthetized rats. All of the acetylenic compounds acted as muscarinic analgesics displaying the same order of potency shown in in vitro studies. The Oxotremorine-like subset showed a clearer distinction between doses producing antinociception and doses exerting undesirable central/peripheral side effects compared to the Oxotremorine-M derivatives. The most promising profile was displayed by the isoxazolin-3-one Oxotremorine-like derivative (compound 1a), which was characterized by a wider therapeutic window than that of the parent molecule Oxotremorine. Indeed, it produced atropine-sensitive analgesia (ID50 about 0.1 mg/kg i.p.) in the absence of tremorogenic (EC50 2.73 mg/kg i.p.) and cardiovascular effects while lethality occurred only at higher doses (LD50 19 mg/kg i.p.). These results suggest that such a derivative could be a candidate for further development of selective muscarinic analgesics. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1775 / 1785
页数:11
相关论文
共 22 条
[1]   Potential role of muscarinic agonists in Alzheimer's disease [J].
Avery, EE ;
Baker, LD ;
Asthana, S .
DRUGS & AGING, 1997, 11 (06) :450-459
[2]   New analogues of oxotremorine and oxotremorine-M - Estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes [J].
Barocelli, E ;
Ballabeni, V ;
Bertoni, S ;
Dallanoce, C ;
De Amici, M ;
De Micheli, C ;
Impicciatore, M .
LIFE SCIENCES, 2000, 67 (06) :717-723
[3]  
BURN JH, 1952, BIOL STANDARDIZATION
[4]   Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M [J].
Dallanoce, C ;
Conti, P ;
De Amici, M ;
De Micheli, C ;
Barocelli, E ;
Chiavarini, M ;
Ballabeni, V ;
Bertoni, S ;
Impicciatore, M .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (08) :1539-1547
[5]  
Damaj MI, 1999, J PHARMACOL EXP THER, V291, P390
[6]   Muscarinic receptor ligands and their therapeutic potential [J].
Eglen, RM ;
Choppin, A ;
Dillon, MP ;
Hegde, S .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) :426-432
[7]  
Ellis JL, 1999, J PHARMACOL EXP THER, V288, P1143
[8]   Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice [J].
Gomeza, J ;
Shannon, H ;
Kostenis, E ;
Felder, C ;
Zhang, L ;
Brodkin, J ;
Grinberg, A ;
Sheng, H ;
Wess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (04) :1692-1697
[9]  
GRIMM U, 1994, PHARMAZIE, V49, P711
[10]   MUSCARINIC RECEPTOR SUBTYPES [J].
HULME, EC ;
BIRDSALL, NJM ;
BUCKLEY, NJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1990, 30 :633-673